Skip to main content
$6.35 -$0.35 (-5.3%)

10:51 AM EDT on 09/25/23

Molecular Templates Inc (NASDAQ:MTEM)

CAPS Rating: No stars

A biotechnology company focused on the discovery and development of small molecule therapeutics for the potential treatment of cancer.

Current Price $6.35 Mkt Cap $36.0M
Open $6.70 P/E Ratio -0.54
Prev. Close $6.70 Div. (Yield) $0.00 (0.0%)
Daily Range $6.24 - $6.77 Volume 4,888
52-Wk Range $4.65 - $12.75 Avg. Daily Vol. 15,148


How do you think NASDAQ:MTEM will perform against the market?

Add Stock to CAPS Watchlist

All Players

94 Outperform
21 Underperform

All-Star Players

6 Outperform
3 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:MTEM Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

smartgainer (< 20)
Submitted September 27, 2016

Clinical trials results for promising cancer drug coming soon.

zzlangerhans (37.74)
Submitted July 07, 2016

Threshold is now trading well over cash after trading at less than half cash earlier this year. That can only mean one of two things: a leak of impending positive data from phase II trials of tarloxitinib, or momentum trader games. Given what I've… More

Fools bullish on NASDAQ:MTEM are also bullish on:

Fools bearish on NASDAQ:MTEM are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about MTEM.


Member Avatar TMFSecurity (93.53) Submitted: 11/16/2021 8:53:08 AM : Underperform Start Price: $79.80 NASDAQ:MTEM Score: +84.23



Member Avatar smartgainer (< 20) Submitted: 9/27/2016 8:09:25 AM : Outperform Start Price: $196.35 NASDAQ:MTEM Score: -197.72

Clinical trials results for promising cancer drug coming soon.


Member Avatar Ted2400 (< 20) Submitted: 9/2/2016 4:52:37 PM : Outperform Start Price: $198.00 NASDAQ:MTEM Score: -198.80

Market cap is only $80 million. Approval of their lead compound would push this to a billion plus company.


Find the members with the highest scoring picks in MTEM.

No players have picked MTEM yet. Tell us why you think MTEM will outperform or underperform against the market.

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for MTEM.